Company Overview and News
The Commerce Commission says Christchurch International Airport may be planning to make excessive profits from security, freight storage, and some terminal lounges, though it's "broadly satisfied" with its planned earnings from most of its assets.
AIA AIA ACKDF AUKNY
Back in May, we published an article introducing a number of publicly-traded airports around the world. Airports deserve attention as an investment as they are wide-moat businesses backed by a secular trend of growing air traffic.
FPRUY AIA ACKDF AUKNY FPRUF VCISY 0694 5014 SYDDF ANNSF AIA VCISF MYPRY SYD HMCTF
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO
Air New Zealand has slammed the "ravages of airport pricing behaviour" in New Zealand in support of changes to the Commerce Act it says would help curb airport owners' charging and cut air travel costs for passengers.
AIA AIA ANZLY AIR ANZFF ANZFY ACKDF AUKNY AIZ
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO
New Zealand shares rallied, pushing the S&P/NZX 50 Index to a record after Fletcher Building detailed its five-year strategy and affirmed guidance. Sky Network Television, A2 Milk, Auckland International Airport and Fisher & Paykel Healthcare rose.
AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY SKT SYKWF AIA PPSHY FBU RYHTY SKKTY SML
New Zealand shares rose, led by Auckland International Airport, Spark and Fisher & Paykel Healthcare and as buyers returned to A2 Milk. Gentrack Group fell as earnings growth disappointed some bullish investors.
AIA WBC AIA WBC GTK WEBNF GXH WBK ACKDF AUKNY PRCXF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET